Browse RMM Directory A-Z

Card for patient's receiving Darzalex (daratumumab)- patient should carry this card while receiving treatment and for 6 months after treatment has ended.

${pdf_link}$

Important information on safety and risk minimisation of Daratumumab and Interference with Blood Compatibility Testing

Information for Blood Banks on the intereference with Antiglobulin Test _blood typing

${pdf_link}$

Daurismo (glasdegib) Patient Alert Card

Patient alert card for male patients regarding the risk of embryo-foetal risks of exposure to women of child-bearing potential by semen associated with DAURISMO

${pdf_link}$

Important Information for Healthcare Professionals

${pdf_link}$

Important information for patients

${pdf_link}$

Physician’s reference checklist for Deferasirox

${pdf_link}$

Deferasirox Important information for patients about your treatment and possible side effects

Please keep this document safe for future reference. This booklet is only intended for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.

${pdf_link}$

Deferasirox Physicians Reference Checklist.

Checklist for dosing and biological monitoring

${pdf_link}$

Important Information to Remember About deferasirox Treatment.

This booklet provides detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment.

${pdf_link}$

Important information for Healthcare Professionals

minimise key adverse effects including medication errors during treatment

${pdf_link}$

Important information for patients about your treatment and possible side effects

Booklet for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.

${pdf_link}$

Physician’s reference checklist for Deferasirox (deferasirox) dosing and biological monitoring

Document highlights important information about requirements for Deferasirox (deferasirox) dosing, dose adjustment and biological monitoring.

${pdf_link}$

Important information for Healthcare Professionals

Booklet with detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment

${pdf_link}$

Important information for Patients

Booklet for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring of your treatment is important, and which medicines you can take while on deferasirox.

${pdf_link}$

Physician´s reference checklist

Checklist for deferasirox dosing, dose adjustment and biological monitoring.

${pdf_link}$

Deferasirox Important information for patients about your treatment and possible side effects

${pdf_link}$

Important Information to Remember About Deferasirox Treatment

${pdf_link}$

Physician’s reference checklist for Deferasirox

${pdf_link}$

Deferasirox HCP Information Brochure

${pdf_link}$

Deferasirox Patient Information Brochure

${pdf_link}$

Deferasirox Physician's Reference Checklist

${pdf_link}$

Deferasirox HCP Information Brochure

${pdf_link}$

Deferasirox Patient Information Brochure

${pdf_link}$

Deferasirox Physician's Reference Checklist

Physicians reference checklist for dosing and monitoring

${pdf_link}$

Valproate- “White Box” Warning Labels

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate Female Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

${pdf_link}$

Valproate- Healthcare professionals (HCPs) Guide

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate Male Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

${pdf_link}$

Valproate- Patient Card-Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate- Patient Guide

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate- Poster- Dispensary- Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

DOSING CARD: Dexamethasone 3.8 mg/ml solution for injection

Dosing Card

${pdf_link}$

Boys 2-18 years growth chart

This chart is mainly intended to assess the growth of school age boys. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years, with the WHO growth standard for children aged 2 years to 4 years. The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.

${pdf_link}$

Chart for ongoing monitoring during Dexamfetamine sulfate treatment

A form template according to prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored.

${pdf_link}$

Dexamfetamine checklist 1

Checklist 1: checklist before prescribing Dexamfetamine sulfate 5 mg tablets

${pdf_link}$

Dexamfetamine checklist 2

Checklist 2: checklist for monitoring of ongoing therapy with Dexamfetamine sulfate 5 mg tablets.

${pdf_link}$

Dexamfetamine consideration

Consideration when ending treatment with Dexamfetamine sulfate 5mg Tablets

${pdf_link}$

Dexamfetamine Pharmacist Information

This sheet provides additional information on Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate).

${pdf_link}$

Dexamfetamine Physician Information

A physician’s guide to prescribing Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate)

${pdf_link}$

Girls UK Growth chart 2-18 years

This chart is mainly intended to assess the growth of school age girls. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years, with the WHO growth standard for children aged 2 years to 4 years. The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.

${pdf_link}$

Information for parents and carers

Information for parents and carers of patients prescribed with Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate)

${pdf_link}$

Dexamfetamine Sulfate 5mg tablets

Educational materials for Dexamfetamine Sulfate 5mg tablets-PL 06464/3115 These materials have been designed to support you in the appropriate prescription and administration of Dexamfetamine Sulfate 5 mg tablets for the treatment of patients with ADHD. It is recommended that these materials be used in conjunction with the full prescribing information for the product.

${pdf_link}$

HCP Educational Material Ferric Derisomaltose

IV iron. Essential Prescription and Administration Information to Minimise the Risk of Serious Hypersensitivity Reactions

${pdf_link}$

Patient Educational Material Ferric derisomaltose

Intravenous (IV) Iron. Important Information for Patients about the Possible Risk of Serious Allergic Reactions with IV iron treatment (iron given by injection or infusion into a vein)

${pdf_link}$

Dianette Patient Card UK

Dianette patient information card.

${pdf_link}$

Dianette Prescriber Checklist UK

Dianette - checklist for prescribers.

${pdf_link}$

Pamidronate Patient Reminder Card

contains important safety information that patients need to be aware of before and during treatment with pamidronate disodium injections

${pdf_link}$

Pamidronate Patient Reminder Card Cover Letter

is a letter which should be viewable only by the HCP. It details the requirement for the dispensing pharmacist to discuss the contents of the Patient Reminder Card with the patient prior to dispensing.

${pdf_link}$

Dronedarone Aristo Prescribers Guide

Safety information for the use of Dronedarone Aristo

${pdf_link}$

Dronedarone 400 mg film-coated tablets

DRONEDARONE PRESCRIBER GUIDE

${pdf_link}$

Patient Card

Information card for women about the risk of blood clots.

${pdf_link}$

Prescriber Checklist

Prescriber checklist to be used in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.

${pdf_link}$

Duodopa Best practice patient aftercare

This short guide provides advice to healthcare professionals on the management of patients with advanced Parkinson’s disease who have started Duodopa therapy

${pdf_link}$

Duodopa Critical Aspects of PEG-J Preparation Placement and Aftercare

The information presented in these slides is provided as part of additional Risk Minimisation Program for Duodopa targeted to minimise: –Gastrointestinal (GI) events –Device-related risks –Procedure-related risks associated with the levodopa – carbidopa intestinal gel (LCIG) system

${pdf_link}$

Duodopa Patient Pocket Guide

This pocket guide provides a practical overview of the Duodopa system and potential complications related to the medication and its delivery system.

${pdf_link}$

Duodopa PEG-J aftercare guideline

This guide provides advice to healthcare professionals on how to minimise PEG-J tube related complications in patients receiving Duodopa therapy. It should be used in conjunction with any local guidance and the CADD-Legacy 1400 pump instruction manual.

${pdf_link}$

Duodopa Safety, PEG-J insertion and aftercare, LCIG System Use and Pump Operations

Important Additional Risk Minimisation Information for Healthcare Professionals Training for AbbVie Duodopa Specialists on LCIG System, PEG-J Placement, Aftercare and Minimisation of Procedure Complications

${pdf_link}$

Valproate - Annual Risk Acknowledgement Form for females GB & NI 2023 - aRMM

Further to the National Patient Safety Alert issued on 28 November 2023, the purpose of this letter is to notify you of an important restriction of indication for new male patients and all female patients aged under 55 years, along with updated contraindications, warnings, and measures to prevent valproate exposure during pregnancy, as well as the availability of revised educational materials to support discussions with patients.

${pdf_link}$

Valproate - Poster-Dispensary-Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme.

${pdf_link}$

Valproate - Risk Acknowledgement Form for males GB & NI 2023 - aRMM

Further to the National Patient Safety Alert issued on 28 November 2023, the purpose of this letter is to notify you of an important restriction of indication for new male patients and all female patients aged under 55 years, along with updated contraindications, warnings, and measures to prevent valproate exposure during pregnancy, as well as the availability of revised educational materials to support discussions with patients.

${pdf_link}$

Risk Minimisation Materials

Dabigatran

Genus Pharmaceuticals

Dabigatran etexilate

Laboratorios Liconsa, S.A.

Darzalex

Janssen-Cilag Ltd (a Johnson & Johnson Company)

Daurismo

Pfizer Limited

Deferasirox

Amarox Limited

Dr. Reddy's Laboratories (UK) Ltd

Glenmark Pharmaceuticals Europe Ltd

MSN Laboratories Europe Ltd

Mylan

Teva UK Limited

Zentiva

Depakote

SANOFI

Dexamethasone

Aspen

Dexamfetamine

Brown & Burk UK Ltd

Sovereign Medical

Diafer

Pharmacosmos UK Limited

Dianette

Bayer plc

Disodium pamidronate

Hospira UK Ltd

Dronedarone

Aristo Pharma Limited

Aurobindo Pharma - Milpharm Ltd.

Drovelis

Gedeon Richter (UK) Ltd

Duodopa

AbbVie Ltd

Dyzantil

Aspire Pharma Ltd

You are trying to reach document intended for healthcare professionals only.